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Abstract
Elevated serum tumor necrosis factor receptor 1 (TNFR1) and 2 (TNFR2) concentrations are 
strongly associated with increased risk of end-stage renal disease in type 2 diabetes. However, 
little is known about the early glomerular structural lesions that develop in patients when these 
markers are elevated. Here we examined the relationships between TNFRs and glomerular 
structure in 83 American Indians with type 2 diabetes. Serum TNFRs and glomerular filtration 
rates (GFR, iothalamate) were measured during a research exam performed within a median of 0.9 
months from a percutaneous kidney biopsy. Associations of TNFRs with glomerular structural 
variables were quantified by Spearman's correlations and by multivariable linear regression after 
adjustment for age, gender, diabetes duration, hemoglobin A1c, body mass index, and mean 
arterial pressure. The baseline mean age was 46 years, median GFR 130 ml/min, median albumin/
creatinine ratio 26 mg/g, median TNFR1 1500 pg/ml, and median TNFR2 3284 pg/ml. After 
multivariable adjustment, TNFR1 and TNFR2 significantly correlated inversely with the 
percentage of endothelial cell fenestration and the total filtration surface per glomerulus. There 
were significant positive correlations with mesangial fractional volume glomerular basement 
membrane width, podocyte foot process width, and percent of global glomerular sclerosis. Thus, 
TNFRs may be involved in the pathogenesis of early glomerular lesions in diabetic nephropathy.
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Introduction
Serum tumor necrosis factor receptor 1 (TNFR1), and receptor 2 (TNFR2) concentrations 
are strong independent predictors of renal function decline leading to end-stage renal disease 
(ESRD) in Caucasians and American Indians with diabetes.
1-4
Although in vitro activated TNFR1 induces tissue injury through proinflammatory signals 
and/or cell death and TNFR2 promotes cell migration, regeneration and proliferation, and 
regulates TNFR1 induced apoptosis,
5
 very little is known about the early glomerular 
structural lesions in kidneys that develop in humans when these markers are elevated. 
Further, since TNFα binds to the TNFRs, it is not known whether these early glomerular 
lesions are associated with the serum concentration of TNFα or with the TNFRs. In one 
small study, TNFR1, but not TNFR2, was associated with higher mesangial fractional 
volume in 22 persons with type 2 diabetes.
6
In the present study, we examined the relationships between serum concentrations of TNFα, 
TNFR1, and TNFR2 and glomerular lesions in American Indians with type 2 diabetes and 
normal or elevated renal function. The glomerular morphometric data were obtained from a 
kidney biopsy performed at the end of a 6-year randomized clinical trial that evaluated the 
renoprotective efficacy of the angiotensin receptor blocker losartan in diabetic nephropathy.
7 
The TNF markers were measured in serum obtained at a research examination coincident 
with the biopsy. The TNF markers that demonstrated univariate associations with glomerular 
structural lesions were further confirmed using multivariable models.
Results
Clinical and demographic characteristics of the study participants are shown in Table 1. The 
study included 83 participants with type 2 diabetes (63 female, 20 male), with a mean age of 
46±10 years. Forty three (52%) had an albumin-to-creatinine ratio (ACR) <30 mg/g, 24 
(29%) had moderate albuminuria (30 to 299 mg/g), and 16 (19%) had severe albuminuria 
(≥300 mg/g). Seventy two (86%) had measured glomerular filtration rate (mGFR, 
iothalamate) above 90 ml/min and 81 (98%) had mGFR above 60 ml/min. When mGFR was 
standardized to body surface area, 66 (79%) had mGFR above 90 ml/min/1.73 m2 and 78 
(94%) were above 60 ml/min/1.73 m2. Hyperfiltration, defined by an mGFR ≥154 ml/min, a 
value two standard deviations above the mean mGFR for Pima Indians with normal glucose 
tolerance, was present in 29 individuals (35%).
Serum concentrations of free TNFα and the TNFRs were measured in samples collected at a 
research examination closest to the kidney biopsy (median of 0.9 months apart, interquartile 
range [IQR]=0.8-1.9 months). Accordingly, 70 participants (84%) were still enrolled in the 
clinical trial. Thirty nine (47%) of the participants were assigned to the placebo group and 
44 (53%) were assigned to the losartan treatment group during the clinical trial. Table 2 
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shows the distribution of measured biomarkers and other clinical characteristics at that 
research examination by the 25th and 75th percentiles of TNFR1 and TNFR2. The mGFR 
was lower (but not significantly so for TNFR2) and ACR was higher with higher 
concentrations of either TNFR. Enrollment in the treatment arm of the clinical trial was 
more common among those in lower percentile groupings of TNFR1 and TNFR2, but not 
significantly so. Several glomerular structural variables were significantly associated with 
percentiles of TNFR1 and TNFR2, as shown in Table 3. Mesangial fractional volume and 
podocyte foot process width were higher with higher TNFR1 and TNFR2 concentrations, 
whereas total filtration surface per glomerulus, and percent of the capillary endothelial cell 
surface covered with normal fenestrations were lower.
TNFR1 and TNFR2 correlated positively with each other (r=0.84, p<0.001) and with ACR 
(r=0.36 and 0.37, respectively; p <0.001 for each correlation), and inversely with mGFR 
(r=-0.35, p=0.001; r=-0.28, p=0.01) (Table 4). Neither TNFR correlated significantly with 
TNFα. Higher TNFR1 and TNFR2 correlated inversely with percentage of normally 
fenestrated endothelium (r=-0.42 and -0.43; p<0.001 for each correlation), total filtration 
surface per glomerulus (r=-0.27, p=0.01; r=-0.29, p=0.007), and filtration slit frequency 
(r=-0.24, p=0.03; r=-0.29, p=0.008), and positively with mesangial fractional volume 
(r=0.36 and 0.38, p<0.001 for both correlations), glomerular basement membrane width 
(r=0.23, p=0.04; r=0.26, p=0.02), and podocyte foot process width (r=0.29, p=0.007; r=0.31, 
p=0.004). TNFR1, but not TNFR2, correlated positively with percent global glomerular 
sclerosis (r=0.25, p=0.02) and inversely with the number of podocytes per glomerulus 
(r=-0.23, p=0.04). TNFα correlated positively with A1c (r=0.27, p=0.02) and MAP (r=0.23, 
p=0.048), but it had no significant univariate correlations with any glomerular variables.
Given the significant univariate associations of the TNFRs with glomerular lesions, these 
relationships were then examined after adjusting for age, sex, diabetes duration, A1c, body 
mass index, and mean arterial pressure (Model 1). Both TNFRs remained significantly and 
inversely correlated with the total filtration surface per glomerulus (TNFR1 partial r=-0.25, 
p=0.03; TNFR2 partial r=-0.28, p=0.009) and percentage of normally fenestrated 
endothelium (TNFR1 partial r=-0.41, p=0.001; TNFR2 partial r=-0.37, p=0.0006) and 
positively with mesangial fractional volume (TNFR1 partial r=0.44, p<0.001; TNFR2 partial 
r=0.38, p=0.0005), glomerular basement membrane width (TNFR1 partial r=0.34, p=0.002; 
TNFR2 partial r=0.30, p=0.006), percent global glomerular sclerosis (TNFR1 partial r=0.22, 
p=0.04; TNFR2 partial r=0.23, p=0.04), and podocyte foot process width (TNFR1 partial 
r=0.30, p=0.006; TNFR2 partial r=0.25, p=0.02). Figure 1 shows the strongest of these 
correlations. The associations between TNFRs and morphometric variables remained 
unchanged after including treatment assignment from the clinical trial in the multivariable 
linear regression models (Model 2, Figure 2). When interaction terms between the TNFRs 
and treatment assignment were added to these models, most were not significant, indicating 
that the relationship between the TNFRs and most morphometric variables was not modified 
by treatment. Treatment assignment did modify the relationship between each TNFR and 
foot process width (p=0.02 for TNFR1, p=0.02 for TNFR2) and filtration slit frequency 
(p=0.001 for TNFR1, p=0.001 for TNFR2).
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Adding ACR and mGFR to the regression models (Model 3) reduced the associations 
between TNFRs and glomerular lesions, but associations remained significant for mesangial 
fractional volume (TNFR1 partial r=0.27, p=0.01; TNFR2 partial r=0.26, p=0.02) and 
percentage of normally fenestrated endothelium (TNFR1 partial r=-0.29, p=0.008; TNFR2 
partial r=-0.25, p=0.02) in the full model (Figure 2). Treatment assignment modified the 
relationship between each TNFR and foot process width (p=0.02 for TNFR1, p=0.02 for 
TNFR2) and filtration slit frequency (p=0.002 for TNFR1, p=0.001 for TNFR2) in these 
models as well. For illustration, Figure 3 shows electron micrographs of glomerular 
endothelium that is either normally fenestrated or has reduced fenestrations. Supplemental 
Figures 1 and 2 show the un-cropped images with scale bars.
When models were examined separately by treatment assignment, the power to detect 
associations between TNFR1 or TNFR2 and the morphometric variables was reduced, but 
the direction of association remained the same in the two subgroups. Furthermore, the 
morphometric variables associated with the TNFRs in the whole group remained associated 
in one or both subgroups (Supplemental Table 1).
Discussion
In the present study, we found that elevated serum concentrations of TNFR1 or TNFR2 in 
patients with type 2 diabetes are associated with early glomerular structural lesions. These 
receptors showed the strongest associations with reduced percentage of normally fenestrated 
endothelium and with increased mesangial fractional volume after controlling for the effects 
of relevant clinical covariates. Weaker associations were found with glomerular basement 
membrane width, podocyte foot process width, and with total filtration surface per 
glomerulus. These findings provide evidence that elevated serum concentrations of TNFRs 
coincide with early lesions in specialized filtration structures in the kidneys of persons with 
type 2 diabetes. Since we found no correlations between free TNFα and the glomerular 
structural lesions, we postulate that the TNFRs, and not TNFα, are the major players in the 
disease process that leads to such early structural lesions.
In previous studies, elevated serum TNFRs,
8-16 increased mesangial fractional volume,
17-19 
and reduced endothelial cell fenestrations associated with elevated albuminuria and low 
GFR,
20,21 but the present study is the first to show correlations between serum TNFR1 and 
TNFR2 and glomerular lesions in patients with type 2 diabetes.
The fenestrated endothelium, covered by the endothelial glycocalyx, represents the 
intraluminal barrier to the passage of macromolecules, including albumin, across the 
glomerular capillary. Normally, fenestrations occupy 30-50% of the glomerular 
endocapillary area and are densely distributed opposite the podocyte foot processes to 
facilitate filtration.
22,23 Loss of endothelial cell fenestrations in glomerular capillaries 
reflects generalized microvascular disease due to persistent hyperglycemia, and is associated 
with low-level albuminuria.
24,25 This endothelial dysfunction also appears to contribute to 
podocyte injury and loss of GFR through several mechanisms.
26
 In a subset of the present 
cohort, we reported previously that the frequency of normally fenestrated endothelium in 
normoalbuminuric patients with type 2 diabetes was significantly lower than in healthy 
Pavkov et al. Page 4













kidney donors (27.4% and 43.5%, respectively) and worsened with higher albuminuria.
20 
The present study confirms these relationships in a larger cohort of participants with type 2 
diabetes, and it also identifies robust and independent inverse correlations between overall 
density of endothelial cell fenestrations and circulating TNFRs. These associations suggest 
that a TNFR-related pathway may link early structural lesions of the glomerular 
endothelium with progression of renal disease in the setting of diabetes.
Mesangial expansion is a structural hallmark of diabetic nephropathy and correlates strongly 
with GFR reduction.
27
 In the present study, TNFRs remained associated with mesangial 
fractional volume after controlling for the effects of traditional risk factors. This finding 
replicates results of a previous cross-sectional study of 22 patients with type 2 diabetes (9 
with normoalbuminuria, 13 with moderate albuminuria)
6
 which found that TNFR1 
correlates with mesangial expansion after controlling for age, body mass index, and blood 
pressure, whereas TNFR2 did not correlate with either mesangial fractional volume or 
cortical interstitial fractional volume, the only two morphometric characteristics included in 
the analysis.
Although the present study describes only cross-sectional associations, a number of earlier 
longitudinal studies have established that elevated levels of circulating TNFRs are powerful 
predictors of renal function decline and ESRD. Indeed, a previous study in Pima Indians 
with type 2 diabetes and preserved kidney function, found that higher serum concentrations 
of TNFR1 or TNFR2 were associated with 60% to 70% higher risk of progression to ESRD 
during a median follow-up of 9.5 years.
4
 Both receptors enhanced the discriminatory power 
of clinically recognized risk factors for kidney disease progression. These findings are 
consistent with our original report from the Joslin Clinic cohort in which we showed a very 
robust association between serum concentrations of TNFRs and the risk of ESRD in 
Caucasians with type 2 diabetes who were followed for 8-12 years.
1
 We also found in 
patients from the Joslin Clinic cohort who had type 1 diabetes, normal or moderate 
albuminuria, and normal kidney function at baseline, that elevated TNFRs predicted 
estimated GFR <60 ml/min per 1.73 m2.
2
 Our present study is also consistent with previous 
reports in which the risks of ESRD or impaired renal function were independent of serum 
free or total TNFα concentrations.
1,2 Among patients with type 1 diabetes who were 
enrolled in the Diabetes Control and Complications Trial (DCCT) and had normal 
albuminuria and no cardiovascular disease at baseline, increased serum TNFR1 and TNFR2 
were associated with 30-50% higher odds of severe albuminuria.
28
 However, the risk of 
impaired renal function according to the baseline concentrations of TNFRs was not reported 
in the DCCT cohort.
Strengths of the present study include a phenotypically well-characterized population with 
kidney disease attributable nearly exclusively to diabetes and in which earlier detection of 
diabetes allows the initial stages of diabetic nephropathy to be studied.
29
 A limitation is the 
cross-sectional design which precludes causal inferences about the associations between 
circulating TNFRs and glomerular morphologic changes. Nevertheless, multiple previous 
prospective studies consistently demonstrate that high serum concentrations of TNFRs 
strongly predict the renal function decline that leads to ESRD, and we now show that 
TNFRs are associated with the principal glomerular structural antecedents of this decline. 
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Another potential limitation is that the study was conducted in the context of a clinical trial 
in which the treatment being evaluated was associated with structural preservation among 
participants with moderate albuminuria. Nevertheless, the conclusions were unchanged 
when we accounted for treatment assignment in the analysis. We also presented results 
separately by treatment assignment, and they are generally consistent with the results from 
the entire cohort (Supplemental Table 1). Each analyte was measured only once, but we 
reported previously that TNFR1 and TNFR2 concentrations are stable over 2-3 years.
2
In summary, elevated serum concentrations of TNFR1 or TNFR2 correlate with glomerular 
structural lesions in patients with type 2 diabetes and normal or high-normal GFR. The most 
prominent correlations are with the percentage of normally fenestrated endothelium and with 
the mesangial fractional volume, after adjusting for the effects of traditional risk factors. 
These findings suggest that the TNFRs may be involved in the pathogenesis of early 
glomerular lesions in diabetic nephropathy.
Materials and Methods
Study Participants
Between 1965 and 2007, Pima Indians from the Gila River Indian Community participated 
in a longitudinal study of diabetes and its complications. Each member of this community 
who was at least 5 years old was invited to have a research examination approximately every 
2 years. Diabetes was diagnosed by a 2-hour post-load plasma glucose concentration ≥200 
mg/dl (11.1 mmol/l) at these biennial examinations, or when the diagnosis was otherwise 
documented in the medical record. For the present study, we selected participants from this 
longitudinal population based study who had type 2 diabetes and also participated in a 6-
year randomized, placebo-controlled clinical trial to evaluate the renoprotective efficacy of 
losartan (ClinicalTrials.gov number NCT00340678).
7
 By design, participants in the clinical 
trial were stratified at baseline into two groups according to the level of urinary albumin 
excretion during screening, and they were randomized to receive either placebo or losartan 
within each group. In one stratum, participants had normal ACR and in the other they had 
moderate ACR, so the study included participants who were clinically normal. The clinical 
trial included annual measurements of GFR by the urinary clearance of iothalamate and a 
kidney biopsy at the end of the treatment period. Treatment was associated with preservation 
of mesangial fractional volume among participants with moderate albuminuria at baseline. 
Of the 111 participants who had morphometric measurements as part of the clinical trial, 83 
who had available serum to measure the TNFRs at the research examination closest to the 
kidney biopsy were included in the present study. Forty-four participants (53%) were in the 
normal ACR stratum at the onset of the clinical trial. TNFα was also measured in a subset of 
74 participants who had sufficient remaining serum volume to do so. This study was 
approved by the Institutional Review Board of the National Institute of Diabetes and 
Digestive and Kidney Diseases. Each subject gave informed consent.
Laboratory Measurements
Laboratory measurements from the research examination closest to the kidney biopsy are 
reported. All urine and serum samples were stored at -80°C until assay. Urinary albumin was 
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measured by nephelometric immunoassay and urinary creatinine by a modified Jaffé 
reaction.
30,31 Urinary albumin concentrations below the threshold detected by the assay 
(<6.8 mg/L) were set to 6.8 mg/L in the analyses. Urinary albumin excretion was estimated 
by computing the urinary ACR in units of mg/g. A1c was measured by high-performance 
liquid chromatography. A high-performance liquid chromatography system also was used to 
measure urinary clearance of non-radioactive iothalamate for GFR determination.
32
Serum concentrations of free TNFα and the TNFRs were measured by ELISA in Dr. A. 
Krolewski's laboratory, Joslin Diabetes Center, Boston, MA, according to the same protocol 
used in the Joslin Kidney Study.
1
 Intra-assay coefficient of variation (CV) for mGFR was 
1.1%, for TNFR1 and TNFR2 were <5%, and for TNFα <10%; the inter-assay CVs were 
2.9%, 16%, 5%, and 15.8%, respectively. Reproducibility of the TNFR assays was assessed 
by intra-class correlation of measurements from 21 duplicate samples blinded to the 
performance laboratory. The intra-class correlation for TNFR1 was 0.92 and for TNFR2 was 
0.99, reflecting good agreement.
Body mass index was defined as weight divided by the square of height (kg/m2). Mean 
arterial pressure was calculated as MAP = 2/3 diastolic arterial pressure + 1/3 systolic 
arterial pressure.
Morphometric Methods
Masked unbiased random sampling morphometric methods were used to measure structural 
parameters.
7
 Digital light and electron micrographs were measured using formal stereologic 
methods to account for two-dimensional sampling of three-dimensional objects.
33 
Morphometric variables examined included mean glomerular volume, percent globally 
sclerotic glomeruli, cortical interstitial fractional volume, mesangial fractional volume, total 
filtration surface per glomerulus, GBM width, number of endothelial cells+mesangial cells 
per glomerulus, number of podocytes per glomerulus, filtration slit frequency, podocyte foot 
process width, percent podocyte detachment, and percentage of normally fenestrated 
endothelium.
7,20,21,28,34 An equation that accounts for the smaller diameter of sclerotic 
glomeruli, and the consequent difference in the probability of encountering a sclerotic or 
nonsclerotic glomerulus in a random cross-section, was used to calculate the percentage of 
sclerotic glomeruli.
35
 An average of 15±6 glomeruli were examined in each participant by 
light microscopy and 3±1 by electron microscopy for the morphometric measurements. 
Glomerular variables for each individual were calculated as the mean of all glomeruli 
evaluated for that individual.
Statistical Analyses
Clinical and demographic features are presented as medians and IQRs or as means and 
standard deviations (SDs) in all participants combined and in three groups of participants 
separated at the 25th and 75th percentiles of TNFR1. The Kruskal-Wallis test was used to 
compare variables across percentiles of TNFR1; Mantel-Haenszel χ2 tests for general 
association were used to examine relationships between TNFR percentiles and the 
categorical variables hypertension, lipid lowering, and hypoglycemic treatment. 
Associations between clinical characteristics, glomerular structural variables, and the 
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biomarkers were explored by Spearman's correlation. Partial correlation analysis was used to 
study the relationships between biomarkers and structural measurements after adjustment for 
the effects of age, sex, diabetes duration, blood pressure, body mass index, and A1c by 
multivariable linear regression (Model 1). Associations between biomarkers and 
morphometric measures were assessed graphically using the partial regression residual plot 
(i.e., plot of the correlation between the residuals from regressing the biomarkers on 
covariates described above and the residuals from regressing morphometric measurements 
on covariates).
Two sensitivity analyses were performed. In the first analysis, treatment assignment from the 
clinical trial was added to the linear regression models (Model 2). In the second, we added 
mGFR and ACR to the linear regression models (Model 3).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Partial regression residual plot of the associations between TNFRs, percentage of normally 
fenestrated endothelium (ECF), and mesangial fractional volume (VvMes). The residuals 
were computed from regressing each of these variables on age, sex, diabetes duration, A1c, 
ACR, mGFR, body mass index, and mean arterial pressure. Exclusion of the single outlier 
did not change the significance of the associations with the two morphometric variables.
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Adjusted correlation coefficients for the associations between TNFRs and renal 
morphometric variables. Model 1 was adjusted for age, sex, diabetes duration, A1c, body 
mass index, and mean arterial pressure; Model 2 included Model 1 covariates and treatment 
assignment from the clinical trial; Model 3 included Model 1 covariates and GFR and ACR. 
ACR, albumin-to-creatinine ratio; BMI, body mass index; ECF, percentage of normally 
fenestrated endothelium; FPW, podocyte foot process width; GBM, glomerular basement 
membrane width; GFR, measured glomerular filtration rate; GS, percent global glomerular 
sclerosis; MAP, mean arterial pressure; TFS, total filtration surface per glomerulus; TNFR, 
tumor necrosis factor receptor; VvMes, mesangial fractional volume. All correlation 
coefficients for Models 1 and 2 are significant; * significant associations for Model 3.
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Peripheral glomerular capillaries from participants with type 2 diabetes. Arrows point to 
capillary endothelium with normal cell fenestrations in a participant with mGFR=189 
ml/min and ACR=13 mg/g (left panel) and with reduced fenestrations in a participant with 
mGFR=73 ml/min and ACR=1031 mg/g (right panel). Transmission electron microscopy, × 
11,280. CL, capillary lumen; FE, fenestrated endothelium; NFE, non-fenestrated 
endothelium; Podo, podocyte; US, urinary space; WBC, white blood cell.
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Table 1
Characteristics of 83 participants with type 2 diabetes.
Clinical Characteristics
Measured Markers
TNFR1 (pg/mL) 1500 (1205-1960)
TNFR2 (pg/mL) 3283 (2670-4151)
TNFα (pg/mL)a 4.1 (2.9-5.7)
Other Characteristics
Age (years)b 46.3 ± 10.1
Diabetes duration (years) 14.1 (11.7-20.3)
Body mass index (kg/m2) 34.2 (29.7-40.0)
A1c (%) 9.2 (7.6-11.2)
Systolic blood pressure (mmHg) 124 (111-132)
Diastolic blood pressure (mmHg) 77 (70-84)
Mean arterial pressure (mmHg) 93 (85-99)
Serum creatinine (mg/dL) 0.67 (0.61-0.80)
ACR (mg/g) 26 (12-127)
mGFR (ml/min) 130 (107-174)
mGFR (ml/min/1.73m2) 119 (94-155)
Hypertension treatment (%)c 45
Diabetes treatment (%) 90
Lipid lowering treatment (%) 30




Mean ± standard deviation
c
n=30 on ACE and 6 on ARB.
ACR, urinary albumin-to-creatinine ratio; A1c, hemoglobin A1c; mGFR, iothalamate glomerular filtration rate; TNFα, tumor necrosis factor α; 
TNFR, tumor necrosis factor receptor.
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Table 2
Characteristics of 83 participants with type 2 diabetes by TNFR1 and TNFR2 percentiles.
Strata of TNFR1 (percentiles)
Clinical Characteristics T1 (n=19) T2 (n=43) T3 (n=21) p
Measured Markers
TNFR1 (pg/mL) 1055 (931-1120) 1500 (1374-1653) 2156 (2039-2564)
TNFR2 (pg/mL) 2214 (1937-2471) 3284 (2935-3629) 4756 (4135-5250) <0.001
TNFα (pg/mL)a 4.6 (3.1-5.9) 4.1 (2.7-5.1) 4.1 (3.0-5.6) 0.82
Other Characteristics
Age (years)b 42.9 ± 9.8 46.4 ± 9.9 49.1 ± 10.3 0.15
Diabetes duration (years) 13.0 (11.2-19.4) 14.0 (11.1-20.5) 15.0 (12.4-22.4) 0.33
Body mass index (kg/m2) 31.4 (27.6-38.4) 33.3 (29.8-40.0) 36.1 (31.7-44.6) 0.14
A1c (%) 9.4 (7.6-10.9) 9.2 (7.5-11.5) 9.2 (7.6-11.2) 0.98
Systolic blood pressure (mmHg) 119 (107-125) 124 (109-132) 127 (117-141) 0.10
Diastolic blood pressure (mmHg) 74 (70-84) 76 (70-83) 82 (72-87) 0.24
Mean arterial pressure (mmHg) 89 (83-98) 92 (85-97) 96 (88-104) 0.11
Serum creatinine (mg/dL) 0.61(0.5-0.67) 0.67 (0.60-0.79) 0.76 (0.68-0.97) <0.001
ACR (mg/g) 18 (12-41) 26 (10-88) 97 (28-923) 0.02
mGFR (ml/min) 150 (117-170) 136 (107-188) 115 (85-133) 0.04
mGFR (ml/min/1.73m2) 136 (117-160) 123 (94-161) 102 (81-110) 0.004
Hypertension treatment (%)c 26 47 57 0.14d
Losartan treatment assignment (%)e 63 58 33 0.11d
Diabetes treatment (%) 89 86 100 0.21d
Lipid lowering treatment (%) 21 33 33 0.62d
Strata of TNFR2 (percentiles)
Clinical Characteristics T1 (n=21) T2 (n=42) T3 (n=20) p
Measured Markers
TNFR1 (pg/mL) 1093 (970-1159) 1509 (1369-1854) 2218 (1981-2585) <0.001
TNFR2 (pg/mL) 2227 (2054-2496) 3290 (2984-3590) 4848 (4561-5390)
TNFα (pg/mL)f 4.6 (3.1-5.9) 3.7 (2.9-4.7) 5.0 (2.5-6.7) 0.34
Other Characteristics
Age (years)b 45.3 ± 9.2 46.9 ± 10.5 48.0 ± 10.6 0.68
Diabetes duration (years) 12.9 (11.3-15.0) 14.3 (11.7-20.9) 15.3 (12.6-19.6) 0.41
Body mass index (kg/m2) 31.4 (28.3-37.7) 33.3 (29.8-39.2) 38.6 (32.1-44.8) 0.09
A1c (%) 9.1 (6.5-10.4) 9.7 (8.3-11.5) 8.8 (7.2-11.4) 0.11
Systolic blood pressure (mmHg) 111 (107-125) 124 (114-132) 126 (117-141) 0.046
Diastolic blood pressure (mmHg) 74 (70-83) 77 (72-83) 79 (70-87) 0.56
Mean arterial pressure (mmHg) 89 (82-95) 93 (87-98) 94 (87-103) 0.17
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Strata of TNFR1 (percentiles)
Clinical Characteristics T1 (n=19) T2 (n=43) T3 (n=21) p
Serum creatinine (mg/dL) 0.65 (0.57-0.69) 0.67 (0.60-0.74) 0.8 (0.66-0.99) 0.009
ACR (mg/g) 18 (12-45) 27 (12-97) 93 (20-978) 0.03
mGFR (ml/min) 142 (126-167) 134 (107-191) 119 (102-141) 0.14
mGFR (ml/min/1.73m2) 134 (117-158) 122 (101-169) 103 (84-121) 0.05
Hypertension treatment (%)g 29 48 55 0.20d
Losartan treatment assignment (%)e 67 50 45 0.33d
Diabetes treatment (%) 81 95 90 0.20d
Lipid lowering treatment (%) 24 36 25 0.53d
T1, TNFR1 and TNFR2 <25th percentile; T2, TNFR1 and TNFR2 25th to 75th percentile; T3, TNFR1and TNFR2 >75th percentile.
TNFR1 values for the 25th percentile cut point=1205 pg/mL, and for the 75th percentile cut point=1960 pg/mL.
TNFR2 values for the 25th percentile cut point=2671 pg/mL, and for the 75th percentile cut point=4152 pg/mL.
Values are medians (25th and 75th centile).
a
n=74; 17; 37; 20.
b
Mean ± standard deviation.
c
T1=2 on ACE and 2 on ARB; T2=17 on ACE and 3 on ARB; T3=11 on ACE and 1 on ARB.
d
P values from Mantel-Haenszel χ2 test for general association.
e
Assigned to receive losartan during clinical trial.
f
n=74; 19; 36; 19.
g
T1=4 on ACE and 1 on ARB; T2=17 on ACE and 3 on ARB; T3=9 on ACE and 2 on ARB.
ACR, urinary albumin-to-creatinine ratio; A1c, hemoglobin A1c; mGFR, iothalamate glomerular filtration rate; TNFα, tumor necrosis factor α; 
TNFR, tumor necrosis factor receptor.
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Table 3
Renal glomerular structural characteristics of 83 participants with type 2 diabetes by TNFR1 percentiles.
Strata of TNFR1 (percentiles)
General Structural Variables T1 (n=19) T2 (n=43) T3 (n=21) p
Mean glomerular volume (×106μ3) 5.5 (4.7-6.4) 5.8 (4.9-6.9) 5.4 (4.2-7.4) 0.46
Glomerular basement membrane width (nm) 513 (367-560) 457 (393-611) 561 (474-649) 0.02
Cortical interstitial fractional volume (%) 30 (28-33) 29 (24-33) 31 (29-35) 0.18
Mesangial fractional volume (%) 17 (13-20) 17 (13-23) 27 (18-32) 0.002
Total filtration surface per glomerulus (×105μ2) 4.2 (3.4-5.1) 4.2 (3.5-5.6) 3.3 (2.3-4.0) 0.02
Non-podocyte number per glomerulus) 3171 (2066-4447) 3696 (2705-4803) 4010 (2991-5377) 0.06
Global glomerular sclerosis (%) 3.3 (0-16.4) 5.4 (0-17.7) 10.2 (0-32.1) 0.30
Podocyte structural variables
Podocyte number per glomerulus 672 (518-724) 610 (462-733) 525 (413-725) 0.46
Filtration slit frequency (slits/mm) 1489 (1266-1648) 1354 (1231-1518) 1296 (1165-1485) 0.08
Foot process width (nm) 409 (378-499) 470 (415-525) 494 (430-570) 0.02
Podocyte detachment (%) 0.28 (0-0.92) 0.46 (0-1.07) 0.56 (0-2.26) 0.83
Endothelial variable
Fenestrated endothelium (%) 31.2 (25.9-37.8) 29.0 (22.3-33.0) 22.9 (17.6-24.5) <0.001
Strata of TNFR2 (percentiles)
General Structural Variables T1 (n=21) T2 (n=42) T3 (n=20) p
Mean glomerular volume (×106μ3) 5.5 (5.0-6.7) 5.7 (4.5-6.8) 5.5 (4.3-7.3) 0.99
Glomerular basement membrane width (nm) 455 (367-556) 503 (411-588) 563 (448-661) 0.06
Cortical interstitial fractional volume (%) 29 (25-33) 30 (24-35) 30 (26-33) 0.87
Mesangial fractional volume (%) 15 (12-19) 20 (14-26) 22 (16-27) 0.01
Total filtration surface per glomerulus (×105μ2) 4.5 (3.7-5.7) 4.2 (3.4-5.1) 3.4 (2.6-4.0) 0.03
Non-podocyte number per glomerulus) 3171 (2360-4447) 3752 (2922-4982) 3863 (2760-4719) 0.32
Global glomerular sclerosis (%) 3.3 (0-13.0) 4.8 (0-16.5) 15.1 (0-32) 0.17
Podocyte structural variables
Podocyte number per glomerulus) 672 (538-733) 604 (462-724) 551 (374-705) 0.21
Filtration slit frequency (slits/mm) 1489 (1290-1621) 1350 (1237-1490) 1252 (1145-1523) 0.03
Foot process width (nm) 415 (388-449) 481 (428-524) 513 (404-571) 0.02
Podocyte detachment (%) 0.10 (0-0.77) 0.39 (0-1.16) 0.55 (0-1.8) 0.64
Endothelial variable
Fenestrated endothelium (%) 32.8 (27.6-36.1) 26.8 (22.15-31.74) 23.4 (18.5- 26.6) <0.001
T1, TNFR1 and TNFR2 <25th percentile; T2, TNFR1 and TNFR2 25th to 75th percentile; T3, TNFR1 and TNFR2 >75th percentile.
TNFR1 values for the 25th percentile cut point=1205 pg/mL, and for the 75th percentile cut point=1960 pg/mL.
TNFR2 values for the 25th percentile cut point=2671 pg/mL, and for the 75th percentile cut point=4152 pg/mL.
Values are medians (25th and 75th centile).
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